Maria Lyng

1.5k total citations
30 papers, 1.0k citations indexed

About

Maria Lyng is a scholar working on Cancer Research, Molecular Biology and Genetics. According to data from OpenAlex, Maria Lyng has authored 30 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Cancer Research, 13 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Maria Lyng's work include Estrogen and related hormone effects (10 papers), MicroRNA in disease regulation (6 papers) and Breast Cancer Treatment Studies (6 papers). Maria Lyng is often cited by papers focused on Estrogen and related hormone effects (10 papers), MicroRNA in disease regulation (6 papers) and Breast Cancer Treatment Studies (6 papers). Maria Lyng collaborates with scholars based in Denmark, United States and Italy. Maria Lyng's co-authors include Henrik J. Ditzel, Anne‐Vibeke Lænkholm, Karina Gravgaard Thomsen, Ann Knoop, Niels Pallisgaard, Harald Binder, Annette Raskov Kodahl, Anne E. Lykkesfeldt, Rolf Søkilde and Thomas Litman and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Maria Lyng

30 papers receiving 1000 citations

Peers

Countries citing papers authored by Maria Lyng

Since Specialization

Citations

This map shows the geographic impact of Maria Lyng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Lyng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Lyng more than expected).

Fields of papers citing papers by Maria Lyng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Lyng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Lyng. The network helps show where Maria Lyng may publish in the future.

Co-authorship network of co-authors of Maria Lyng

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Lyng. A scholar is included among the top collaborators of Maria Lyng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Lyng. Maria Lyng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer 2018 ·Breast Cancer Research ·Carla L. Alves, Daniel Eliáš, Maria Lyng, Martin Bak, Henrik J. Ditzel	32
2	Coexisting genomic aberrations associated with lymph node metastasis in breast cancer 2018 ·Journal of Clinical Investigation ·Li Bao, Zhaoyang Qian, Maria Lyng, Ling Wang, Yuan Yu, Ting Wang, Xiuqing Zhang, Huanming Yang, Nils Brünner, Jun Wang, Henrik J. Ditzel	22
3	High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·Carla L. Alves, Daniel Eliáš, Maria Lyng, Martin Bak, Tove Kirkegaard, Anne E. Lykkesfeldt, Henrik J. Ditzel	53
4	Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer 2016 ·Oncotarget ·Tejal Joshi, Daniel Eliáš, Jan Stenvang, Carla L. Alves, Fei Teng, Maria Lyng, Anne E. Lykkesfeldt, Nils Brünner, Jun Wang, Ramneek Gupta, Christopher T. Workman, Henrik J. Ditzel	33
5	Prospective validation of a blood‐based 9‐miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography 2016 ·Molecular Oncology ·Maria Lyng, Annette Raskov Kodahl, Harald Binder, Henrik J. Ditzel	15
6	Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients 2015 ·Breast Cancer Research and Treatment ·Karina Gravgaard Thomsen, Maria Lyng, Daniel Eliáš, (unknown), Ann Knoop, Anne E. Lykkesfeldt, Anne‐Vibeke Lænkholm, Henrik J. Ditzel	11
7	miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonizationin vivoand causes significant signaling alterations 2015 ·Oncotarget ·Karina Gravgaard Thomsen, Mikkel G. Terp, Rikke Raaen Lund, Rolf Søkilde, Daniel Eliáš, Martin Bak, Thomas Litman, Hans Christian Beck, Maria Lyng, Henrik J. Ditzel	17
8	High expression of CDK6 protects breast cancer cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant treatment in estrogen receptor-positive metastatic breast cancer 2015 ·University of Southern Denmark Research Portal (University of Southern Denmark) ·Carla L. Alves, Daniel Eliáš, Maria Lyng, Martin Bak, Anne E. Lykkesfeldt, Henrik J. Ditzel	2
9	Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study 2014 ·Molecular Oncology ·Annette Raskov Kodahl, Maria Lyng, Harald Binder, Søren Cold, Karina Gravgaard Thomsen, Ann Knoop, Henrik J. Ditzel	148
10	Evaluation of the ability of adjuvant tamoxifen‐benefit gene signatures to predict outcome of hormone‐naive estrogen receptor‐positive breast cancer patients treated with tamoxifen in the advanced setting 2014 ·Molecular Oncology ·Anieta M. Sieuwerts, Maria Lyng, Marion E. Meijer‐van Gelder, Vanja de Weerd, Fred C.G.J. Sweep, John A. Foekens, Paul N. Span, John W.M. Martens, Henrik J. Ditzel	13
11	Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease 2013 ·Leukemia & lymphoma ·Ida Bruun Kristensen, Jacob Haaber Christensen, Maria Lyng, Michael Møller, Lise Pedersen, Lars Melholt Rasmussen, Henrik J. Ditzel, Niels Abildgaard	27
12	Gene Expression Signatures That Predict Outcome of Tamoxifen-Treated Estrogen Receptor-Positive, High-Risk, Primary Breast Cancer Patients: A DBCG Study 2013 ·PLoS ONE ·Maria Lyng, Anne‐Vibeke Lænkholm, Qihua Tan, Werner Vach, Karina Gravgaard Thomsen, Ann Knoop, Henrik J. Ditzel	8
13	CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial 2012 ·JNCI Journal of the National Cancer Institute ·Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell’Orto, Maria Olivia Biasi, Beat Thürlimann, Maria Lyng, Henrik J. Ditzel, Patrick Neven, Marc Debled, Rudolf Maibach, Karen N. Price, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch, James M. Rae, Giuseppe Viale	229
14	Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study 2012 ·PLoS ONE ·Maria Lyng, Anne‐Vibeke Lænkholm, Rolf Søkilde, Karina Gravgaard Thomsen, Thomas Litman, Henrik J. Ditzel	53
15	The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer 2012 ·Breast Cancer Research and Treatment ·Karina Gravgaard Thomsen, Maria Lyng, Anne‐Vibeke Lænkholm, Rolf Søkilde, Boye Schnack Nielsen, Thomas Litman, Henrik J. Ditzel	83
16	Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer 2012 ·Acta Oncologica ·(unknown), Ann Knoop, Karsten Bjerre, Mathilde Skaarup Larsen, Katrine L. Henriksen, Maria Lyng, Henrik J. Ditzel, Birgitte Rasmussen, Nils Brünner, Bent Ejlertsen, Anne‐Vibeke Lænkholm	11
17	Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors 2009 ·Breast Cancer Research ·Thomas Frogne, Anne‐Vibeke Lænkholm, Maria Lyng, Katrine L. Henriksen, Anne E. Lykkesfeldt	65
18	Identification of genes for normalization of real-time RT-PCR data in breast carcinomas 2008 ·BMC Cancer ·Maria Lyng, Anne‐Vibeke Lænkholm, Niels Pallisgaard, Henrik J. Ditzel	93
19	Advantages of multiple clinical tests for determining the optimum treatment strategy for ER-positive breast cancer 2008 ·Nature Clinical Practice Oncology ·Henrik J. Ditzel, Maria Lyng	1
20	Intratumor Genetic Heterogeneity of Breast Carcinomas as Determined by Fine Needle Aspiration and TaqMan Low Density Array 2007 ·Analytical Cellular Pathology ·Maria Lyng, Anne‐Vibeke Lænkholm, Niels Pallisgaard, Werner Vach, Ann Knoop, Martin Bak, Henrik J. Ditzel	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact